Emiliem, Inc is a private biotechnology company focused on understanding the molecular determinants of target modulation as it relates to the efficacy of therapeutics and to potential adverse drug reactions. The company is particularly interested in diagnostic markers for rare diseases and the computational aspects of predicting both positive and negative patient outcomes.